Thank you for submitting your manuscript entitled 'Cell adhesion defines the topology of endocytosis and signaling'. I have now received the three reports on your paper.
The attached reports indicate principle interest in your study. However, all scientists conclude that the paper would significantly benefit if some amendments and additional experiments and controls could be provided to further support your data and claims. I would like to focus your attention specifically to try to generalize the observed key effects by using another polarized cell line, to provide data for EGF/Tf localization prior to internalization, and to test a non-multivalent ligand for EGF. Furthermore, the data and conclusions on MAPK/Akt should be carefully revised. Based on amendments that constructively address the concerns, I would like to invite you to submit a revised version of the manuscript. I should also add that it is EMBO Journal policy to allow only a single round of revision and that it is therefore important to address the concerns raised at this stage. Please do not hesitate to contact me in case of further questions or to outline the timeframe for necessary experimental work. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
-----------------------------------------------REFEREE COMMENTS
Referee #1
In this manuscript, Grossier and colleagues have characterized the asymmetric distribution of EGF and Transferrin (Tf) endocytosis using RPE-1 cells grown in micropattern devices. Consistent with previous reports, they show that endocytosis of Tf occurs in adhesive hotspots, and that endocytosis of EGF is polarized to the dorsal part of the cell. Taking advantage of micropatterned cell arrays, they provide a novel way of quantifying this phenomenon, using 3D probabilistic distributions. Using this method, they showed for the first time that F-actin is a key factor for the polarized distribution of EGF and Tf endocytosis. Finally, they reveal that EGFR dimerization is also polarized to the dorsal part of the cell, and that disruption of F-actin causes non-polarized EGFR signaling, a decrease in Akt phosphorylation, and thus, a switch in EGFR downstream signaling. Although the manuscript provides evidence supporting the proposed model, the reach of the findings is limited and further experiments are required for publication in EMBOJ.
MAJOR POINTS 1-The main caveat of this work is that most findings were characterize in a specific cell type, and just supported by in vitro data using micropatterns. Furthermore, it relies on previous data about endocytic hotspots to support the importance of the findings. Therefore, the authors should show if actin fibers and actin polymerization drive the polarization of endocytic hotspots in a more physiological model, and demonstrate whether EGF and Tfn internalization is also polarized in other models. For instance, culturing polarized epithelial cells (MDCK or CACO-2) on micropatterns would allow the analysis of a basal and a lateral surface internalization in cells which actin structures are differentiated. Fig. 2B ) appears to be stronger at the dorsal region of the cell. However, in the 50% density map, EGFR seems to be greatly localized at the ventral part. Is this due to the spatial orientation of the density map (which does not show z axis)? It would be also interesting to show EGFR and TfnR distribution in the absence of their ligands, and also for clathrin and AP2.
2-The EGFR localization (
3-Related to the mechanism of polarized endocytosis, F-actin availability has been proven to be essential to control certain processes such as migration and ciliogenesis. The amount of actin available for adhesion and tension restricts the amount of free actin required for other processes such as endocytosis, and in particular it could restrict processes where massive actin polymerization is required, such as during EGFR endocytosis. For example, increasing contractility inhibits ciliogenesis, and it is stimulated with CD treatments. In the case of polarized endocytosis of EGFR, it appears to be the opposite, since F-actin disruption depolarizes its internalization. Is it thus possible to modify EGF or Tfn endocytosis by increasing or decreasing the micropattern size to modify cell contractility, and thus F-actin availability? At least in theory, more stretched cells would have less available apical actin, and less dorsal EGF internalization.
4-The authors show that CD treatment increases clathrin and EGF colocalization (Fig. 3C ), without greatly affecting the level of EGF internalization ( Supplementary Fig. 3D ). Is there a switch in the endocytotic mechanism? Clathrin siRNA + CD treatments should prove if such a switch really exists. In order to elucidate the potential mechanism it would be also interesting to show whether this switch also occurs with other treatments described in the article.
5-The changes observed in Akt signaling upon depolarization of EGF endocytosis are quite interesting. However, they are observed only under CD treatment, which again may have induced pleiotropic effects. This is not properly discussed in the conclusions, and the authors simply assume this is caused by depolarization of EGF endocytosis. The authors should try other means of depolarizing EGF endocytosis and show the same effects on Akt phosphorylation. Additionally, the authors should show Akt and P-Akt localization by IF and probabilistic density maps with and w/o CD. 6-The internalization of Tfn on the adhesive side of the cell causes its transport into Rab11+ endosomes, while EGF is transported to Rab7+ endosomes. When Tfn or EGF endocytosis is depolarized (for instance, with CD), the co-localization pattern with Rab5 does not change (consistent with no decrease in their total internalization). What about their transport and colocalization with Rab7 or Rab11 endosomes? Is post-Rab5 trafficking still polarized in CD-treated cells? Or their destination is independent on the internalization/polarity mechanism.
MINOR POINTS 1-The article would also benefit from other additional experiments. For instance, what is the effect of laying EGF into the micropattern as ECM coating? Can they force basal EGF internalization in that way? What would happen to EGF/Akt signaling in that case? For biochemistry experiments, EGF could be laid to the bottom of a culture dish together with fibronectin coating. Would this inflict changes in P-Akt signaling as well? 2-In Figure 4A , page 5, "all around the cell...", the reference is not correct. Figure 4A 5-The methodology of deriving a graphic representation of a probabilistic map is not clear enough for the people that have not read the methodology section in the original article and should be further detailed. Readers should not be required to read the previous article to understand the figures in the new manuscript.
3-

Referee #2
In this study, the authors present a novel strategy for quantitatively analyzing cell surface receptor endocytosis -that is to use a single cell (human retinal pigment epithelial cells) assays to monitor the uptake of fluorescently labeled transferrin (Tfn) and epidermal growth factor (EGF). Using this approach, the authors are able to ask an important, yet fundamental, scientific question: "Is ligand endocytosis random or does uptake occur from specific areas of the plasma membrane". In fact, the authors demonstrate there is a preference that is unique to each of the tested ligands. EGF is taken up primarily along the dorsal membrane of the cell, whereas, Tfn is internalized from the bottom of the cell.
The authors appropriately acknowledge in the text, that these differences can not be simplified to ligand differences. The caveat to this study is that the concentration of EGF used is at a concentration that has been previously be reported to promote clathrin-independent EGF:EGFR internalization. Nevertheless, their findings do highlight the differences in two different routes of entry. In addition, this manuscript reports that EGF uptake, but not transferrin uptake was altered when actin was disrupted. The authors use multiple approaches to disrupt the actin cytoskeleton and found all changed the distribution of EGF uptake from primarily a dorsal localization to one that was more uniform around the cell.
In the second part of the study, the authors examine EGFR signaling when the actin cytoskeleton is disrupted via the addition of cytocholasin D. The authors point out this will alter the topology of EGFR endocytosis and propose that they can compare receptor and effector (MAPK and AKT) activity from receptors at different cellular locations. However, the interpretation of these data are not that simple. The first and foremost problem is that EGF dependent EGFR phosphorylation is attenuated by the addition of cytocholasin D ( Figure 4A and 4B -2 minute time point). One possible explanation for this is that the actin cytoskeleton is necessary for EGF:EGFR binding and/or EGFR phosphorylation. Regardless of the cause of the reduction in receptor phosphorylation, it prevents a meaningful interpretation downstream signaling events. How can one tell if reduced MAPK and AKT phosphorylation is due to reduced receptor activity or inappropriate spatial regulation of the receptor?
The authors specifically examine EGFR phosphorylation using FRET and the EGFR tyrosine kinase inhibitor AG1478 ( Figure 4C -E). They show that in control cells EGFR phosphorylation is different at the bottom and top of the cell. When the actin cytoskeleton is disrupted, the EGFR phosphorylation is similar regardless of receptor location. In this regard, since EGFR phosphorylation is different, one could argue that EGFR signaling is different based on topology in the cell. However, to include MAPK and AKT in the interpretation is misleading, as there is no indication if the change in effector activity is due to changes in EGFR phosphorylation or receptor:effector coupling.
Minor criticism: 1. p.4 the molecular weights of the EGF and Tfn fluorescent conjugates seem too high.
Referee #3
In this paper, authors quantified the sites of Tf and EGF endocytosis by 3D probabilistic density maps in micro-patterned cells, so that the geometry of adhesion was set. They report that Tfn endocytosis occurred primarily on the ventral side, while EGF endocytosis was restricted to the dorsal surface, and that this separation was not due to receptor distribution. They also report that actin regulates this differential distribution, and that Tfn distribution depends on clathrin and AP2 recruitment to the ventral side. Finally, they report that asymmetric EGF uptake leads to an asymmetry in the EGF induced signal initiation that is sensitive to actin depolymerization. They conclude that cellular adhesion cues determine signal propagation in an outside-in mechanism by restricting endocytosis to distinct sites. This paper is interesting, but some issues need to be addressed. In particular, authors conclude that, because adhesion is defined by micro-patterning, adhesion cues determine endocytosis and signal propagation (Fig 1C-D) . However, the link between adhesion, endocytosis and signaling remains rather vague.
Other comments
1) It is stated (p3) that cells were treated with 1microg/ml EGF conjugate and that EGF concentration was 100ng/ml. What does it mean? Does it mean that all incubations were in the presence of 1microg/ml EGF conjugate and 100ng/ml free EGF? If so, given the 10X size difference, EGF and EGF conjugate were present at the same concentration, which is relatively high (approximately 15 microM). Why was free EGF added? Is it necessary? Does it make any difference if free EGF is omitted?
2) The authors did not use free, labeled EGF, but a complex of biotin-EGF and labeled streptavidin. This should be made very clear at the beginning of the Results section. More important, streptavidin is multivalent. Is it cleat that the pattern of EGF distribution is not caused by the multi-valency of the ligand?
3) I find it very surprising that EGF endocytosis was completely insensitive to clathrin depletion ( Fig S2B) . As I understand it, the present consensus in the field is that EGFR is always endocytosed by the clathrin pathway, and in addition by another pathway at least in some cell types. Could this behavior be due to the use of polyvalent EGF? 4) Conversely, I also find it surprising that filipin reduced the EGF signal very significantly. Since fluorescent EGF was added to the cells and since fluorescent structures were scored, how was endocytosed EGF discriminated from EGF still on the cell surface. How was the normalization carried out? Does it mean that the number of receptors on the cell surface is reduced after 1h filipin treatment?
5) The EGFR receptor is concentrated on the dorsal portion of the cell. Actin depolymerization causes a redistribution of EGFR (Fig 3) but also a reduction in EGFR phosphorylation (Fig 4A-B) . I can understand that the site of endocytosis may affect EGF downstream signaling. However, it is not clear to me why cytochalasin-induced EGFR redistribution should affect ligand-induced EGFR trans-phosphorylation (Fig 4A-B) , since internalization itself is not affected (Fig S3D) .
Minor comments
In the EGF or Tf pulse-chase experiments, cells are labeled for 1min at 37C, washed in ice-cold PBS and then chased at 37C. The difference in EGF and Tf distribution (Fig 1C-D) is shown at 1min post pulse. Do EGF and Tf show the same distribution as the receptors (Fig 2A-B) when added on ice?
In the Y-Z projection (Fig 2C) , clathrin does not show the same distribution as Tf after 1min internalization (Fig 1C) . At least on my copy, clathrin seems equally distributed on the ventral and dorsal sides of the cell. Referee #1
In this manuscript, Grossier and colleagues have characterized the asymmetric distribution of EGF and Transferrin (Tf) endocytosis using RPE-1 cells grown in micropattern devices. Consistent with previous reports, they show that endocytosis of Tf occurs in adhesive hotspots, and that endocytosis of EGF is polarized to the dorsal part of the cell. Taking advantage of micropatterned cell arrays, they provide a novel way of quantifying this phenomenon, using 3D probabilistic distributions. Using this method, they showed for the first time that F-actin is a key factor for the polarized distribution of EGF and Tf endocytosis. Finally, they reveal that EGFR dimerization is also polarized to the dorsal part of the cell, and that disruption of F-actin causes non-polarized EGFR signaling, a decrease in Akt phosphorylation, and thus, a switch in EGFR downstream signaling. Although the manuscript provides evidence supporting the proposed model, the reach of the findings is limited and further experiments are required for publication in EMBOJ.
We thank the referee for her/his overall positive evaluation of our work. As requested, we have performed new experiments to support our model.
MAJOR POINTS 1-The main caveat of this work is that most findings were characterize in a specific cell type, and just supported by in vitro data using micropatterns. Furthermore, it relies on previous data about endocytic hotspots to support the importance of the findings. Therefore, the authors should show if actin fibers and actin polymerization drive the polarization of endocytic hotspots in a more physiological model, and demonstrate whether EGF and Tfn internalization is also polarized in other models. For instance, culturing polarized epithelial cells (MDCK or CACO-2) on micropatterns would allow the analysis of a basal and a lateral surface internalization in cells which actin structures are differentiated.
-The topology of Tfn and EGF was investigated in 3 other cell lines, including polarized cell models (Caco-2 and LLC-PK1). Similar results as in RPE-1 cells were obtained that are shown in the new Supplementary Fig. 2 and described on page 4 -highlighted in yellow). The topology of Tfn and EGF was sensitive to actin disruption in HeLa and LLC-PK1 cells. However, this was not the case in Caco-2 cells. This is likely due to differences in the architecture of the actin cytoskeleton between Caco-2 and the three other cell lines as shown in Supplementary Fig. 2E and described on page 7. Therefore, we now state in the Discussion that "As the actin cytoskeleton shows strong variations between different cell lines, uptake topology of ligands may vary substantially between different cell lines." (page 10, last sentence of 2 nd paragraph).
-We have removed statements about hot spots not directly addressed by our data.
2-The EGFR localization (Fig. 2B) appears to be stronger at the dorsal region of the cell. However, in the 50% density map, EGFR seems to be greatly localized at the ventral part. Is this due to the spatial orientation of the density map (which does not show z axis)? It would be also interesting to show EGFR and TfnR distribution in the absence of their ligands, and also for clathrin and AP2.
-Density maps show the z-axis and reveal that in a cell population the distribution of the EGFR is all over the cell and not concentrated on the dorsal surface. We show in the revised version an image that better illustrates this point (Fig. 2B ).
-The distribution of the EGFR, TfnR and clathrin was tested in the presence and absence of the ligand and does not change. To clarify this point, we have added on page 4/5: "The distributions of the TfnR and EGFR did not change in the presence and absence of their ligands.", and "The distribution of clathrin was similar in the presence and absence of Tfn. The distribution of AP2 was only tested in the absence of Tfn, because methanol fixation was used in these experiments that was not compatible with Tfn fluorescence. This is a good point and we have indeed performed EGF/Tfn uptake experiments on patterns of different sizes, choosing a small pattern of 20 µm, a medium size pattern of 30 µm and a large one of 60 µm that was the maximal size for full spreading. We used disc-shaped patterns for all sizes for better comparison. However, we did not observe any major changes in the distribution of EGF that always concentrated on the upper surface of the cell independent of the size of the pattern. A reason could be that modifications in cell contractility induced by varying the sizes of the patterns were not of enough amplitude to change the topology of EGF uptake. We did not add these results in the manuscript. Fig. 3D ). Is there a switch in the endocytotic mechanism? Clathrin siRNA + CD treatments should prove if such a switch really exists. In order to elucidate the potential mechanism it would be also interesting to show whether this switch also occurs with other treatments described in the article.
3-Related to the mechanism of polarized endocytosis, F-actin availability has been proven to
4-The authors show that CD treatment increases clathrin and EGF colocalization (Fig. 3C), without greatly affecting the level of EGF internalization (Supplementary
-This is a very interesting point and we have performed additional experiments to address it. We performed gene silencing of clathrin + CD treatment and observed indeed a decrease in EGF uptake. However, the cells are in a bad shape under this condition making it difficult to unambiguously draw conclusions. Therefore, we did not include these results but quantified the co-localization in the TIRF movies and performed co-localization analysis under different conditions (see below) that keep the cells in a better physiological state.
-To address in more detail uptake mechanisms of EGF we varied EGF concentration and performing co-localization analysis of EGF and clathrin. Decreasing the effective EGF concentration to 10 ng/ml, which should favor clathrin-dependent uptake increased the co-localization between EGF and clathrin. Additionally, we find that mild actin disruption with Cytochalasin D increased colocalization between EGF and clathrin. We have restructured the manuscript and moved data from Supplementary Fig. 2 to the main manuscript. Together our data shown in the new Fig. 2G and Fig.  4B ,C implicate that in RPE-1 cells EGF uptake is partly clathrin-dependent and increases under cytochalasin D treatment. However, this process seems to be fully compensated upon clathrin depletion. To highlight these findings we have modified the manuscript on page 5 (middle part), page 7 (upper part) and page 9/10 -all in yellow.
-Additionally, we analyzed co-localization between EGF and Tfn under different conditions and find an increase in co-localization with all drugs tested shown in Supplementary Fig. 3G and described on page 7. -We agree that the depolymerisation of actin may have a pleiotropic effect on Akt. We have restructured the Discussion to highlight this point on page 10/11 and additionally state: "However, we cannot exclude that actin has a more indirect effect on downstream effectors by inhibiting their proper recruitment. Future studies will aim at addressing this issue."
5-The changes observed in
-We have additionally monitored Akt and MAPK phosphorylation after inhibition of the actomyosin network with Blebbistatin and obtained similar results of decreased signaling. These results are presented on page 8 (middle part) and in Supplementary Fig. 5A .
-We have performed Akt and p-Akt localization by IF and probabilistic density maps with and w/o CD. The IF staining of Akt/p-Akt is diffuse and cytosolic giving rise to density maps that are not very defined in all tested conditions. Although EGF addition increased the number of pAkt-positive structures, the IF stainings of Akt and p-Akt were not specific enough to specifically localize Akt and p-Akt and reveal differences in density maps.
6-The internalization of Tfn on the adhesive side of the cell causes its transport into Rab11+ endosomes, while EGF is transported to Rab7+ endosomes. When Tfn or EGF endocytosis is depolarized (for instance, with CD), the co-localization pattern with Rab5 does not change (consistent with no decrease in their total internalization). What about their transport and colocalization with Rab7 or Rab11 endosomes? Is post-Rab5 trafficking still polarized in CD-treated cells? Or their destination is independent on the internalization/polarity mechanism.
These are interesting questions that we plan to address in future studies. We believe that they are out of the scope of this manuscript.
MINOR POINTS 1-The article would also benefit from other additional experiments. For instance, what is the effect of laying EGF into the micropattern as ECM coating? Can they force basal EGF internalization in that way? What would happen to EGF/Akt signaling in that case?
-We have laid labeled EGF in addition to fibronectin on micropatterns prior cell seeding and have observed that cell spreading was inhibited under these conditions resulting in very little cells that attached to micropatterns. Observation of the localization of fluorescent EGF in the few cells attached to the micropatterns after three hours incubation indicated that EGF was present on the plasma membrane and inside the cell as well as still on the micropattern. Unfortunately, we cannot interpret these experiments taking into account the experimental difficulties.
-Experiments that monitor EGF/Akt signaling in cells seeded on EGF as ECM are not experimentally possible as mentioned above. Additionally, the presence of EGF as coating reagent will already stimulate cells thus modifying EGF/Akt signaling prior to the planned experiment.
For biochemistry experiments, EGF could be laid to the bottom of a culture dish together with fibronectin coating. Would this inflict changes in P-Akt signaling as well?
As stated above, experiment that monitor EGF/Akt signaling in cells seeded on EGF as ECM are not conclusive as the presence of EGF as coating reagent will already stimulate cells thus modifying EGF/Akt signaling prior to the planned experiment. Figure 4A , page 5, "all around the cell...", the reference is not correct.
2-In
We are sorry for this mistake and have corrected the numbering. Figure 4A regards P-Akt.
3-
We have clarified to p-Akt and p-ERK1/2 on page 8. Fig 4CD should 
4-In page 6,
random or does uptake occur from specific areas of the plasma membrane". In fact, the authors demonstrate there is a preference that is unique to each of the tested ligands. EGF is taken up primarily along the dorsal membrane of the cell, whereas, Tfn is internalized from the bottom of the cell. The authors appropriately acknowledge in the text, that these differences can not be simplified to ligand differences. The caveat to this study is that the concentration of EGF used is at a concentration that has been previously be reported to promote clathrin-independent EGF:EGFR internalization. Nevertheless, their findings do highlight the differences in two different routes of entry. In addition, this manuscript reports that EGF uptake, but not transferrin uptake was altered when actin was disrupted. The authors use multiple approaches to disrupt the actin cytoskeleton and found all changed the distribution of EGF uptake from primarily a dorsal localization to one that was more uniform around the cell.
We thank the referee for her/his overall positive evaluation of our work. We would like to comment that we report that actin disruption alters both EGF and Tfn uptake topology, however, the effects are stronger on EGF uptake.
In the second part of the study, the authors examine EGFR signaling when the actin cytoskeleton is disrupted via the addition of cytocholasin D. The authors point out this will alter the topology of EGFR endocytosis and propose that they can compare receptor and effector (MAPK and AKT) activity from receptors at different cellular locations. However, the interpretation of these data are not that simple. The first and foremost problem is that EGF dependent EGFR phosphorylation is attenuated by the addition of cytocholasin D (Figure 4A and 4B -2 minute time point). One possible explanation for this is that the actin cytoskeleton is necessary for EGF:EGFR binding and/or EGFR phosphorylation. Regardless of the cause of the reduction in receptor phosphorylation, it prevents a meaningful interpretation downstream signaling events. How can one tell if reduced MAPK and AKT phosphorylation is due to reduced receptor activity or inappropriate spatial regulation of the receptor?
We have carefully re-examined the phosphorylation of the EGFR performing additional experiments and statistical testing on the results. We conclude that EGFR activation is not significantly altered in the presence of Cytochalasin D. We have modified the Results on page 8 (upper section). The immunoblot results together with the data from the FRET measurement indicate that the global level of EGFR phosphorylation is similar in the presence and absence of Cytochalasin D. Therefore, it seems that reduced phosphorylation of MAPK and AKT is not due to receptor activity. However, we agree that the results on Akt and MAPK signaling are difficult to interpret as actin disruption may have pleiotropic effects and need more investigation in the future (see also response to point 5 raised by referee 1). We have modified the Discussion to highlight this point on page 10/11.
The authors specifically examine EGFR phosphorylation using FRET and the EGFR tyrosine kinase inhibitor AG1478 (Figure 4C -E). They show that in control cells EGFR phosphorylation is different at the bottom and top of the cell. When the actin cytoskeleton is disrupted, the EGFR phosphorylation is similar regardless of receptor location. In this regard, since EGFR phosphorylation is different, one could argue that EGFR signaling is different based on topology in the cell. However, to include MAPK and AKT in the interpretation is misleading, as there is no indication if the change in effector activity is due to changes in EGFR phosphorylation or receptor:effector coupling.
As stated above, we agree that the results on Akt and MAPK signaling are difficult to interpret as actin disruption may have pleiotropic effects (see also referee 1). We have modified the Discussion accordingly and now state: "However, we cannot exclude that actin has a more indirect effect on downstream effectors by inhibiting their proper recruitment. Future studies will aim at addressing this issue." to highlight this point on page 10.
Minor criticism: 1. p.4 the molecular weights of the EGF and Tfn fluorescent conjugates seem too high.
We have verified the molecular weights of the EGF and Tfn fluorescent conjugates and state that these are the weights provided by the manufacturer. (Fig 1C-D) . However, the link between adhesion, endocytosis and signaling remains rather vague.
Referee #3
In this paper, authors quantified the sites of Tf and EGF endocytosis by 3D probabilistic density maps in micro-patterned cells, so that the geometry of adhesion was set. They report that Tfn endocytosis occurred primarily on the ventral side, while EGF endocytosis was restricted to the dorsal surface, and that this separation was not due to receptor distribution. They also report that actin regulates this differential distribution, and that Tfn distribution depends on clathrin and AP2 recruitment to the ventral side. Finally, they report that asymmetric EGF uptake leads to an asymmetry in the EGF induced signal initiation that is sensitive to actin depolymerization. They conclude that cellular adhesion cues determine signal propagation in an outside-in mechanism by restricting endocytosis to distinct sites.
This paper is interesting, but some issues need to be addressed. In particular, authors conclude that, because adhesion is defined by micro-patterning, adhesion cues determine endocytosis and signal propagation
We thank the referee for her/his overall positive evaluation of our work. We believe that our study clearly illustrates that adhesion and endocytosis are tightly linked as well as the topology of endocytosis and EGFR activation. We agree that the effects on downstream Akt and MAPK signaling events are less strong, mainly because these events are difficult to study, in particular at the single cell level. We have modified the Discussion to take into account the referee's comment.
Other comments 1) It is stated (p3) that cells were treated with 1microg/ml EGF conjugate and that EGF concentration was 100ng/ml. What does it mean? Does it mean that all incubations were in the presence of 1microg/ml EGF conjugate and 100ng/ml free EGF? If so, given the 10X size difference, EGF and EGF conjugate were present at the same concentration, which is relatively high (approximately 15 microM). Why was free EGF added? Is it necessary? Does it make any difference if free EGF is omitted?
There is NO free EGF in the experiments. As calculated by the referee, a conjugate concentration of 1microg/ml corresponds to 100ng/ml EGF as the EGF conjugate is 10 times heavier then free EGF. We apologize for the confusion and have clarified this point on page 3.
2) The authors did not use free, labeled EGF, but a complex of biotin-EGF and labeled streptavidin. This should be made very clear at the beginning of the Results section. More important, streptavidin is multivalent. Is it cleat that the pattern of EGF distribution is not caused by the multi-valency of the ligand?
We now state at the beginning of the Results section that: "Of note, the EGF-conjugate being a complex of biotin-EGF and labeled streptavidin, the effective concentration of EGF was 100 ng/ml." (page 3). We have performed additional experiments with rhodamine-EGF that is mono-valent shown in Supplementary Fig. 3A , D. We obtained the same results with both fluorescently-labeled EGF molecules, indicating that the pattern of EGF distribution is not caused by the multi-valency of the ligand.
3) I find it very surprising that EGF endocytosis was completely insensitive to clathrin depletion (Fig S2B). As I understand it, the present consensus in the field is that EGFR is always endocytosed by the clathrin pathway, and in addition by another pathway at least in some cell types. Could this behavior be due to the use of polyvalent EGF?
We have addressed in more detail uptake mechanisms of EGF by varying EGF concentration and performing co-localization analysis of EGF and clathrin. Decreasing the effective EGF concentration to 10 ng/ml, which should favor clathrin-dependent uptake increased the colocalization between EGF and clathrin. Additionally, we find that mild actin disruption with Cytochalasin D increased co-localization between EGF and clathrin. To clarify this point (that was also raised by referee 1), we have restructured the manuscript and moved data from Supplementary  Fig. 2 to the main manuscript. Together our data shown in the new Fig. 2G and Fig. 4B ,C implicate that in RPE-1 cells EGF uptake is partly clathrin-dependent and increases under cytochalasin D treatment. However, this process seems to be fully compensated upon clathrin depletion. To highlight these findings we have modified the manuscript on page 5 (middle part), page 7 (upper part) and page 10 (upper part) -all in yellow.
4) Conversely, I also find it surprising that filipin reduced the EGF signal very significantly. Since fluorescent EGF was added to the cells and since fluorescent structures were scored, how was endocytosed EGF discriminated from EGF still on the cell surface. How was the normalization carried out? Does it mean that the number of receptors on the cell surface is reduced after 1h filipin treatment?
A mild acidic wash was performed to discriminate between endocytosed EGF and EGF bound to the cell surface. To better emphasize this point we have added this statement into to the Matherial and Method section. EGF structures were counted in control and filipin-treated cells by segmentation using the same profile, and numbers were normalized to the number of structures found in the control experiment. We found about 80 % less structures in filipin-treated cells than in control. The standard deviation is from two independent experiments, which were performed on different days in the same manner. We did not analyze the number of EGFR after filipin treatment, however, it was shown that filipin treatment inhibits clathrin-independent EGFR endocytosis, so we do not expect that the number of EGFR will decrease (according to Sigismund et al. 2008) . (Fig 3) but also a reduction in EGFR phosphorylation (Fig 4A-B) . (Fig 4A-B) , since internalization itself is not affected (Fig S3D) .
5) The EGFR receptor is concentrated on the dorsal portion of the cell. Actin depolymerization causes a redistribution of EGFR
I can understand that the site of endocytosis may affect EGF downstream signaling. However, it is not clear to me why cytochalasin-induced EGFR redistribution should affect ligand-induced EGFR trans-phosphorylation
-The EGFR is NOT concentrated on the dorsal surface of the cell. Indeed, density maps revealed that the distribution of the EGFR is all over the cell. In the revised version, we show an image that better illustrates this point (Fig. 2B )(see also response to the point 2 raised by referee 1).
-We have carefully re-examined the phosphorylation of the EGFR performing additional immunoblot experiments and statistical testing on the results. We conclude that EGFR activation is NOT significantly altered in the presence of Cytochalasin D. The immunoblot results together with the data from the FRET measurement indicate that the global level of EGFR phosphorylation is similar in the presence and absence of Cytochalasin D (see also response to point 5 raised by referee 1). We have adjusted the Results on page 8 (middle section) and Discussion on page 10/11.
Minor comments
We have added experimental data on EGF and Tfn internalization at 4°C on page 6 (lower part). We find that Tfn was internalized from the entire lower surface and EGF internalization was observed all around the cell, similar to conditions in which actin was disrupted and similar to receptor distribution. Analysis of the actin cytoskeleton revealed that actin cytoskeleton was altered at 4°C reinforcing the hypothesis that actin dynamics plays an important role in the topology endocytosis, as indicated on page 6.
In the Y-Z projection (Fig 2C) , clathrin does not show the same distribution as Tf after 1min internalization (Fig 1C) . At least on my copy, clathrin seems equally distributed on the ventral and dorsal sides of the cell.
Density maps reveal that clathrin are concentrated above adhesive sites. We show in the revised version an image that better illustrates this point (Fig. 2C ) . However, we agree that clathrin is an abundant protein that is found around the cell as mentioned on page 10 (last sentence of first paragraph) and its 75% and 90% density maps correspond to those of Tfn.
2nd Editorial Decision 28 August 2013
Thank you for submitting the revised version of your manuscript entitled 'Cell adhesion defines the topology of endocytosis and signaling'. I have now received the reports from two of the three original referees on your paper, which you can find below.
Both referees appreciate the introduced changes. However, a few issues remain that need to be addressed to allow further proceedings here, particularly regarding possible clathrin-mediated EGF uptake.
Please clarify the points raised by the referees and do not hesitate to contact me in case of further questions.
I am looking forward to reading your revised manuscript!
In this revised version of the manuscript, Grossier and colleagues have addressed most of the major issues raised on their characterization of endocytosis using micropatterned cells. The main observation of the manuscript continues to be the asymmetric distribution of EGF and Transferrin (Tf) endocytosis in RPE-1 cells. In the new version of the manuscript, the authors have validated this result in other cell types, helping to broaden the meaning of their data. Consistent with previous reports, they show that endocytosis of Tf occurs in adhesive hotspots, and that endocytosis of EGF is polarized to the dorsal part of the cell. Together with referee #3, we had raised some issues on the quality of the images that now appear properly corrected in the new version. Furthermore, additional quantification of most imaging experiments is provided, although regretfully most of these results do not show statistical analysis. Taking advantage of micropatterned cell arrays, the authors provide a novel way of quantifying this phenomenon, using 3D probabilistic distributions, which are now more properly described in the methods section. To disrupt polarized endocytosis, the authors still focus on the role of the actin cytoskeleton. The use of cytochalasin D to disrupt F-actin was raised particularly as a troubling point by all referees, since it may have several pleiotropic effects that ultimately affect endocytosis and downstream signaling. The authors have repeated some of these experiments using blebbistatin, which disrupts actomyosin, and have also toned down the depth of the conclusions according to the pleiotropic nature of the treatments they use.
The new manuscript provides more in-depth evidence supporting the proposed model, although we still have additional qualms on two major points. The authors observed that cells treated with clathrin heavy chain siRNA display no difference in the rate of EGF endocytosis. Additionally, the authors observed an increase in EGF/clathrin colocalization when treating cells with cytochalasin D, correlating with a ventralization of EGF distribution. We asked the authors if clathrin could mediate EGF endocytosis when actin is disrupted by cytochalasin D. The authors provided an answer to this point, implying they had carried out the experiment and the results suggested that this switch in endocytic mechanism of EGF was indeed occurring. However, they present no data from these experiments, arguing that the cells were in bad shape. If the authors can see this difference, even if cells are in "bad shape", why cannot they show the results? If the observation is to be considered as an answer to this point, they should show their result, with the appropriate controls, at least as supplementary data or in a rebuttal letter.
The second point we have is related to the localization of receptors in absence of ligand. The authors suggest they performed the experiment, but since the localization is the same as with the ligand, they again chose not to show it. The image should be shown as supplementary data, or at least in a rebuttal letter. Provided the authors present an answer to this two concerns in a final version, we believe the manuscript is fit for publication in EMBO journal.
Referee #3
In this revised version, the authors have addressed most of my specific comment in a satisfactory manner. They show that the sites of EGF and Tf endocytosis are different in adhesive cells, and that asymmetric EGF uptake is actin-dependent. These data are convincing and interesting. However, the links between EGF-R signaling, actin and adhesion remain vague. It is not clear to what extent the effects of the treatments that affect actin are direct or indirect.
I have an additional comment concerning the TIRF analysis (Fig 4) without (movies 1-2) or with (movies 3-4) cytochalasin D. This analysis clearly shows that EGF distribution is affected by cytochalasin D. However, I realize now that most sites labeled with GFP-clathrin, which contain Tf (movie 1 and 4) or EGF (movie 3), do not fluctuate much and persist throughout the time-course of the experiments (1min) particularly after cytochalasin D treatment. By contrast, many Tf-or EGFlabeled structures are highly dynamic and contain little if any visible GFP-clathrin (this is not easily determined in these movies). The latter dynamic structures are likely to be EGF or Tf endocytic sites, and the former structures may well be clathrin-coated lattices. If so the colocalization of EGF or Tf with clathrin (Fig 4B-C) does not mean very much when it comes to the uptake mechanism. For example, it seems that without drug (movie 2) the (few) red EGF dots are transiently associated with green GFP-clathrin. This would argue that EGF is endocytosed primarily via clathrin and challenge one of the conclusions. 
EGFR (+ EGF pulse)
Provided the authors present an answer to this two concerns in a final version, we believe the manuscript is fit for publication in EMBO journal.
We hope that with these answers our revised manuscript will be suitable for publication in The EMBO Journal.
Referee #3
In this revised version, the authors have addressed most of my specific comment in a satisfactory manner. They show that the sites of EGF and Tf endocytosis are different in adhesive cells, and that asymmetric EGF uptake is actin-dependent. These data are convincing and interesting.
We thank referee 3 for his/her comments that allowed us to improve our manuscript.
However, the links between EGF-R signaling, actin and adhesion remain vague. It is not clear to what extent the effects of the treatments that affect actin are direct or indirect.
We would like to stress that using the FRET probe we directly show that EGFR signaling is altered at the lower adhesive site when the actin cytoskeleton is altered revealing the direct link between cell adhesion, EGFR signaling and actin. We agree with the referee however, that downstream signaling of Akt and MAPK are more difficult to interpret and have therefore carefully revised our interpretation on the EGFR downstream signaling. Additionally, we have toned down our conclusions and we have performed experiments with blebbistatin, which disrupts actomyosin showing similar results.
I have an additional comment concerning the TIRF analysis (Fig 4) without (movies 1-2 (Fig 4B-C) does not mean very much when it comes to the uptake mechanism.
Life time measurements indicate that average endocytosis of clathrin-coated pits requires on average 87 s, with fastest endocytic events requiring about 20 s (Taylor et al. 2011) and that life time increases slightly after addition of actin targeting drugs (Boulant et al., 2011) . Thus, it is expected that within a time course of 120 s (2 min) that is shown in the paper a lot of pits should be stable/persistent for at least 20 frames, as observed. (We have chosen to show 2 min to be consistent with experiments in fixed cells). Similarly, the fast fluctuations observed with Tfn and EGF are too fast to be endocytic events (contrary to the opinion of the referee) and we think they are noise (passage of ligands in and out of the optical plane).
For example, it seems that without drug (movie 2) the (few) red EGF dots are transiently associated with green GFP-clathrin. This would argue that EGF is endocytosed primarily via clathrin and challenge one of the conclusions.
We would like to stress that many more EGF structures are observed on the dorsal cell membrane than on the lower cell membrane in micropatterned cells (as revealed with density maps and Zprojections). Because TIRF microscopy only shows the lower cell membrane, only very few EGF structures are visible in TIRF that co-localize with clathrin. We thus conclude that only a very small fraction of EGF seems to be taken up by clathrin-coated pits (as discussed in the manuscript on page 10, now in magenta). This is not against our conclusion that the majority of EGF is taken up clathrin independent on the dorsal cell membrane.
Minor comments
1) Fig S3G shows that drugs that affect actin increase colocalization 2-3 fold. However, what is the normalized colocalization (Y-axis)? How was this calculated? What is the percent of each ligand that colocalizes under control conditions (DMSO)?
To normalize we first calculated the percentage of co-localizing structures of total EGF structures (co-localizing structures/total EGF structures). This percentage was normalized to the corresponding control experiment that was set to 1. Standard deviations show results from 2-4 experiments. In control condition, 5.71±1.94% of EGF structures were found co-localized (shown in Fig S3G) . If we calculate similarly for Tfn, 18.13±6.57% of Tfn structures were found co-localized in control condition. (We chose to represent the EGF results due to context of the paragraph that focuses on EGF.) The corresponding NOT normalized graphs for all conditions are below:
2) In it stated (p6) that cytochalasin D changes the topology of Tf and EGF uptake. This is a bit confusing since Tf topology does not change much (micro-pattern to whole lower cell surface).
We have added on page 6 to clarify (in magenta): "Although this change in Tfn/AP2 topology was subtle, it demonstrated that concentration of Tfn uptake/AP2 at cell-matrix interaction sites is dependent on the actin cytoskeleton."
3) AG1478 does not dephosphorylate EGFR (p8), but inhibits its tyrosine kinase activity
We apologize for the incorrect phrasing and have modified on page 8 (in magenta): Addition of the drug AG1478 that inhibits EGFR tyrosine kinase activity and thus leads to the dephosphorylation of EGFR increased FRET ratio in all parts of the cell.
We hope that with we could clarify all raised points. I have now received the final referee comments on your manuscript, which you can find below. Could you please address the remark of referee #1 in your text/discussion? You can send me the edited text document by email and we will upload it then. We would also need for the final version of the supplementary information a file without the highlighted text, please. Again, you can send this simply by email.
As the beauty of your paper is the highly quantitative readout of your analysis, I would like to encourage you at this point to also provide the source data for your figures. As you might know, we now encourage the publication of source data, with the aim of making primary data more accessible and transparent to the reader. This is not an obligation, but in case you would like to provide the files (excel/spreadsheets and uncropped blots) we would very much appreciate this. For blots, we would need 1 file per figure in jpg, gif or PDF format. These files will be published online with the article as a supplementary "Source Data". Please let me know if you have any questions about this policy.
Thank you very much, I am looking forward to receiving your revised manuscript.
------------------------------------------------REFEREE COMMENTS
Referee #1:
In this revised version of the manuscript, Grossier and colleagues have addressed with more data two major points concerning EGF uptake in cells treated with cytochalasin D, and the localization of the receptors with or without ligand. We asked the authors to show if clathrin could mediate EGF endocytosis when actin is disrupted by cytochalasin D. The authors now provide new results that they claimed suggest that this switch in endocytic mechanism of EGF was indeed occurring. However, the new data that the authors present was poorly analyzed and inconclusive. In fact, although it seems to be a reduction in EGF uptake when clathrin is knocked down and cells are treated with cytochalasin D, it does not seems to be significant. I understand the technical difficulties of this experiment, and thus I will not ask for more experiments. However, I think they should modify the conclusions of this experiment, and state that disruption of the actin cytoskeleton increases co-localization between EGF and clathrin, but whether this lead to a switch in the uptake mechanism should be analyzed more carefully in future studies. The authors have addressed my second specific comment in a satisfactory manner.
